Physician profile
Leslie E Klein
NPI 1619101771
$16,589.13
in general payments reported to CMS, 2019-2025
78 companies · $2,564 in 2025
The $2,564 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,730 · 2020: $1,138 · 2021: $2,061 · 2022: $3,518 · 2023: $3,308 · 2024: $2,271 · 2025: $2,564.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,043 · Education: $101.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,042.69 |
| Education | $100.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $1,076.58 | 2019-2025 | Opdivo, Opdualag, Pomalyst |
| Pfizer INC. | $964.73 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $944.17 | 2019-2025 | |
| Genentech USA, INC. | $830.73 | 2019-2025 | Phesgo, Perjeta, Alecensa |
| Merck Sharp & Dohme LLC | $788.75 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Genzyme Corporation | $772.67 | 2019-2025 | |
| Janssen Biotech, INC. | $772.36 | 2019-2025 | Darzalex, Tecvayli, Imbruvica |
| Astrazeneca Pharmaceuticals Lp | $712.73 | 2019-2025 | Imfinzi, Lynparza, Enhertu |
| Amgen INC. | $676.95 | 2019-2023 | Vectibix, Nplate, Xgeva |
| Abbvie INC. | $642.97 | 2022-2025 | |
| Seagen INC. | $585.88 | 2020-2023 | Tukysa, Adcetris, Padcev |
| Pharmacyclics LLC, An Abbvie Company | $442.78 | 2019-2023 | Imbruvica, Epkinly |
| Lilly USA, LLC | $371.96 | 2019-2023 | Verzenio |
| Daiichi Sankyo INC. | $368.95 | 2019-2025 | Enhertu, Datroway, Injectafer |
| Astellas Pharma US INC | $365.31 | 2019-2023 | Padcev, Xospata, Xtandi |
Show all 78 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leslie Klein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.